IL6 and COVID-19: The IgM auto-antibody expansion is a condition that has been shown to correlate with upregulation of IL-6 (and IL-10) [73], suggesting that it might both be sustained by a compensatory inflammatory response and be inhibited by IL-6-targeted therapies, which could be more effective, for example, in specific cases of COVID-19 IgM expansion.